Jay Rothstein

Biography

 Dr. Rothstein is a translational immunobiologist with experience in lead discovery, PK/PD, toxicological assessment and POC models for immune modulatory drugs. Prior to ImmuNext he was Director of Inflammation Research at Amgen where he championed a novel class of immunomodulatory drugs for the treatment of autoimmune disease. He was involved in evaluating and developing Amgen's early immune-oncology drug pipeline including novel bispecifics such as BiTEs and checkpoint inhibitors. In addition, he developed novel drugs to target immunometabolism. Dr. Rothstein received his Ph.D. in Tumor Immunology from the University of Chicago and was Professor of Otolaryngology-HNS at the Kimmel Cancer Institute of Thomas Jefferson University for 13 years. Prior to his industrial research his laboratory was responsible for discovering an association between oncogenes and chronic inflammation leading to a better understanding of the tumor microenvironment.

Research Interest

 Immunology